REVEL A randomized double blind phase III study of docetaxel DOC and ramucirumab RAM IMC 1121B versus DOC and placebo PL in the treatment of stage IV non small cell lung cancer NSCLC following disease progression after one prior platinum based therapy


Perol M., Ciuleanu T., Arrieta O., Prabhash K., Syrigos K., GÖKSEL T. , ...Daha Fazla

0th Annual Meeting of the American Society of Clinical Oncology, Chicago, Amerika Birleşik Devletleri, 03 Temmuz 2014 identifier

  • Basıldığı Şehir: Chicago
  • Basıldığı Ülke: Amerika Birleşik Devletleri